Astellas Pharma Canada Appoints New President

Astellas Pharma Canada Appoints New President

MARKHAM, ON, June 29 /CNW Telbec/ - Astellas Pharma Canada, Inc. ('Astellas Pharma Canada') announced today that Michael Tremblay has been appointed president of the Canadian subsidiary of Astellas Pharma Inc. His predecessor, Fumiaki Sakurai, will return to Japan to assume a new role in the company's Asia International Division.

"Mike has made many significant contributions to Astellas Pharma Canada and I am very pleased that he will now be acting as president," said Seigo Kashii, president and CEO of Astellas Pharma US, Inc. with responsibility for business in the Americas. "His demonstrated leadership and excellent track record will prove invaluable to Astellas as he drives the implementation of our strategic plan for growing our business in Canada."

Mr. Tremblay has almost 35 years of broad experience in the pharmaceutical industry, spanning areas of sales and marketing, business development, training and customer relationship management. Mr. Tremblay has been with Astellas for ten years, and since 2007, has acted as vice president of Sales and Marketing for the company. In his new role as president, Mr. Tremblay will lead the Canadian executive team while enhancing and growing Astellas' business presence in Canada.

About Astellas Pharma Canada

Astellas Pharma Canada, Inc., a Canadian affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to improving the health of people around the world through innovative and reliable pharmaceutical products. Astellas was formed in 2005 through the merger of two companies - Fujisawa and Yamanouchi. Astellas Pharma Canada has an intense focus on five key therapeutic areas - Infectious Disease, Immunology, Cardiology, Urology and Dermatology - and is considered a leader in these fields. Additional corporate information is available at<>.


For further information: Michelle Reale, Corporate Communications, Astellas Pharma Canada, Inc., (905) 946-5621, [email protected]